Chief Medical Officer

• Executive ownership of a high-value, differentiated neurotoxin asset
• Meaningful equity upside in a VC-backed growth platform

About Our Client

We are partnering with a venture capital-backed biotech developing a next-generation injectable neurotoxin platform for aesthetic indications. As the company advances into late-stage development and U.S. regulatory engagement, we are seeking a Chief Medical Officer to lead clinical strategy through FDA approval and support future commercialization.

Job Description

Key Responsibilities

• Lead Phase II/III global clinical trial design and execution for injectable neurotoxin aesthetic indications
• Serve as the primary medical interface with the FDA (End-of-Phase, pre-BLA, BLA support)
• Define clinical endpoints, safety strategy, and benefit-risk positioning aligned with regulatory and commercial goals
• Build and leverage strong KOL and investigator networks in aesthetics, dermatology, and plastic surgery
• Oversee medical affairs strategy, scientific communications, and advisory boards
• Partner with CRO and Regulatory, Clinical Ops, Commercial, and BD experts
• Present clinical strategy and data to the Board and investors

MPI does not discriminate on the basis of race, religion, sex, sexual orientation, gender identity or expression, age, disability, marital status, or based on an individual's status in any group or class otherwise protected under applicable human rights legislation. MPI encourages applications from minorities, women, the disabled and all other qualified applicants.

The Successful Applicant

A successful Chief Medical Officer should have:

• MD (or equivalent) required
• Demonstrated hands-on leadership of late-stage clinical programs through FDA approval
• Deep experience in injectable aesthetics / neurotoxins or closely related therapeutic areas
• Prior senior medical leadership experience (CMO, SVP, VP Clinical/Medical)
• Strong FDA engagement experience and credibility with external stakeholders
• Established KOL relationships within the U.S. and global aesthetics community
• Particularly well-suited for senior medical leaders from global leading aesthetic-focused organizations who are ready to take full ownership of an asset and shape its trajectory from late-stage development to market.

What's on Offer

• Executive ownership of a high-value, differentiated neurotoxin asset
• Direct influence on clinical, regulatory, and medical strategy
• Meaningful equity upside in a VC-backed growth platform
• Opportunity to transition from large pharma to a high-impact, decision-driving CMO role

If you are ready to take on this exciting Chief Medical Officer role, apply now to join a leading organization in the financial services industry.

Contact

Annie Shen

Quote job ref

JN-122025-6896750